# US 2020/0390738 A1 · Topical formulations of chloroprocaine and methods of using same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390738 A1
- Document ID: US20200390738A1
- Status: Published application
- Kind: A1
- Application number: 17/008,913
- Filed: 2020-09-01
- Published: 2020-12-17
- Earliest claimed: 2017-09-15
- Assignees: Sintetica S.A.
- Applicants: Sintetica S.A.
- Inventors: Augusto Mitidieri; Elisabetta Donati; Clara Bianchi
- Web page: https://patentgrep.com/patent/US20200390738A1

## CPC

- A61K 31/245: Amino benzoic acid types, e.g. procaine, novocaine (salicylic acid esters A61K31/60)
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 47/02: Inorganic compounds
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/38: Cellulose; Derivatives thereof
- A61P 23/02: Local anaesthetics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Topical dosages and formulations of chloroprocaine and pharmaceutically acceptable salts thereof are provided that are efficacious, chemically stable and physiologically balanced for safety and efficacy, particularly during ophthalmic procedures or in response to ophthalmic abrasions or trauma.

## Claims

### Claim 1

1) A topical formulation for inducing local analgesia or anesthesia comprising:
a) a therapeutically effective amount of chloroprocaine or a pharmaceutically acceptable salt thereof for inducing said local analgesia or anesthesia;
b) one or more thickening agents; and
c) water.

### Claim 2

2) A topical gel formulation for inducing local analgesia or anesthesia comprising:
a) a therapeutically effective amount of chloroprocaine or a pharmaceutically acceptable salt thereof for inducing said local analgesia or anesthesia;
b) one or more thickening agents; and
c) water.

### Claim 3

3) An ophthalmic gel formulation for inducing local analgesia or anesthesia comprising:
a) a therapeutically effective amount of chloroprocaine or a pharmaceutically acceptable salt thereof for inducing said local analgesia or anesthesia;
b) one or more thickening agents; and
c) water.

### Claim 4

4) The formulation of any of the foregoing claims for inducing local analgesia or anesthesia without inducing significant irritation or toxicity.

### Claim 5

5) The formulation of any of the foregoing claims for inducing local anesthesia or analgesia on the corneal surface during ocular surgery or in response to a corneal abrasion or trauma.

### Claim 6

6) The formulation of any of the foregoing claims comprising from 2% to 4% by weight chloroprocaine or a pharmaceutically acceptable salt thereof.

### Claim 7

7) The formulation of any of the foregoing claims comprising from 2% to 4% by weight chloroprocaine HCl or a pharmaceutically acceptable salt thereof.

### Claim 8

8) The formulation of any of the foregoing claims comprising about 3% by weight chloroprocaine HCl.

### Claim 9

9) The formulation of any of the foregoing claims wherein said thickening agent is selected from the group consisting of cellulose derivatives, natural gums, and inorganic compounds.

### Claim 10

10) The formulation of any of the foregoing claims wherein said thickening agent is selected from the group consisting of methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, xanthan gum, guar gum, pectin, aluminum silicate, magnesium aluminum silicate, silica, and combinations thereof.

### Claim 11

11) The formulation of any of the foregoing claims wherein said formulation comprises from 0.5% to 1.5% by weight hydroxyethyl cellulose.

### Claim 12

12) The formulation of any of the foregoing claims wherein said formulation comprises from 0.6% to 1.4% by weight hydroxyethyl cellulose.

### Claim 13

13) The formulation of any of the foregoing claims further comprising an acidic pH adjusting agent.

### Claim 14

14) The formulation of any of the foregoing claims further comprising an acidic pH adjusting agent in an amount sufficient to impart a pH of from 2.8 to 3.8 to the formulation.

### Claim 15

15) The formulation of any of the foregoing claims further comprising an acidic pH adjusting agent in an amount sufficient to impart a pH of from 3.0 to 4.0 to the formulation.

### Claim 16

16) The formulation of any of the foregoing claims further comprising hydrochloric acid, lactic acid, citric acid and tartaric acid.

### Claim 17

17) The formulation of any of the foregoing claims further comprising hydrochloric acid in an amount sufficient to impart a pH of from 2.8 to 4.0 to the formulation.

### Claim 18

18) The formulation of any of the foregoing claims comprising hydroxyethyl cellulose in an amount sufficient to impart a viscosity of from 300 to 1500 mPas.

### Claim 19

19) The formulation of any of the foregoing claims comprising:
a) 3% by weight chloroprocaine HCl;
b) 0.6% to 1.4% hydroxyethyl cellulose;
c) hydrochloric acid q.s. to pH 2.8-4.0; and
d) purified water q.s. to 100%.

### Claim 20

20) The formulation of any of the foregoing claims comprising:
a) 3% by weight chloroprocaine HCl;
b) hydroxyethyl cellulose q.s. to 600-1400 mPas;
c) hydrochloric acid q.s. to pH 2.8-4.0; and
d) purified water q.s. to 100%.

### Claim 21

21) The formulation of any of the foregoing claims wherein the formulation is sterile.

### Claim 22

22) The formulation of any of the preceding claims wherein the water is water degassed by nitrogen bubbling.

### Claim 23

23) The formulation of any of the foregoing claims having a viscosity of from 300 to 1500 mPas, as measured by a BrookField DV II+Pro Spindle 3 at 100 rpm, as described in section 2.2.10 of the European Pharmacopeia 2016 edition.

### Claim 24

24) The formula of any of the foregoing claims in the form of a gel, lotion, ointment, paste or cream.

### Claim 25

25) The formulation of any of the foregoing claims in the form of a monodose package comprising from 0.5 to 2 grams of gel.

### Claim 26

26) The formulation of any of the foregoing claims which is clear or translucent.

### Claim 27

27) The formulation of any of the foregoing claims capable of passage through a hydrophilic cartridge having a pore width of from 0.22 to 0.45 microns at 40° C. to 70° C. under pressure from air or nitrogen.

### Claim 28

28) A method of manufacturing the formulation of any of the foregoing claims comprising admixing said chloroprocaine or pharmaceutically acceptable salt, said one or more thickening agents, a pH adjuster, and said water to make a formulation.

### Claim 29 (depends on 28)

29) The method of claim 28 comprising:
a) admixing said one or more thickening agents, said pH adjuster, and water to make a placebo matrix,
b) thermally sterilizing the placebo matrix,
c) admixing chloroprocaine or a pharmaceutically acceptable salt thereof with water and optionally a pH adjuster to prepare a drug solution,
d) sterilizing said drug solution by filtering said drug solution through a filter having a pore width of from 0.22 to 0.45 microns, and
e) mixing the placebo matrix and the drug solution to make said formulation.

### Claim 30 (depends on 28, 29)

30) The method of claim 28 or 29 comprising admixing 3% by weight chloroprocaine HCl, 0.25 to 2.0% hydroxyethyl cellulose, hydrochloric acid q.s. to pH 2.8-4.0, and purified water q.s. to 100% to make the formulation.

### Claim 31 (depends on 28, 29)

31) The method of claim 28, 29, or 30, further comprising filling said formulation into containers in the presence of air.

### Claim 32 (depends on 31)

32) The method of claim 31, wherein said containers are monodose containers comprising from 0.5 to 2 grams of gel formulation.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

33) A method of inducing local analgesia or anesthesia in a mammalian subject in need thereof comprising topically administering to said mammal the formulation of any of claims 1-27.

### Claim 34 (depends on 33)

34) The method of claim 33 for inducing local analgesia or anesthesia without inducing significant irritation or toxicity.

### Claim 35 (depends on 33, 34)

35) The method of claim 33 or 34 for inducing local anesthesia or analgesia on the corneal surface during ocular surgery or in response to a corneal abrasion or trauma.

### Claim 36 (depends on 33, 34, 35)

36) The method of claim 33, 34 or 35, for inducing local anesthesia or analgesia on the corneal surface during cataract surgery, treatment for maculopathy, conventional glaucoma surgery, vitrectomy, surgeries for diabetic nephropathy, or laser surgery.
